About Proteasomal ubiquitin receptor ADRM1
Proteasomal ubiquitin receptor ADRM1 (ADRM1) is a protein
from Homo sapiens identified by UniProt accession
Q16186, 407 residues long.
MolForge cross-references it against 0 known binders and
125 disease associations.
Target properties
| Protein name | Proteasomal ubiquitin receptor ADRM1 |
|---|
| UniProt accession | Q16186 |
|---|
| Gene | ADRM1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 407 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (125)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- glioblastoma multiforme · score 0.23
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- Familial prostate cancer · score 0.11
- hepatocellular carcinoma · score 0.09
- breast cancer · score 0.07
- neoplasm · score 0.07
- multiple myeloma · score 0.06
- lymphocyte count · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q16186-F1 | alphafold | PREDICTED | 62.29 | — |
Amino-acid sequence (407 residues)
MTTSGALFPS LVPGSRGASN KYLVEFRAGK MSLKGTTVTP DKRKGLVYIQ QTDDSLIHFC WKDRTSGNVE DDLIIFPDDC EFKRVPQCPS GRVYVLKFKA GSKRLFFWMQ EPKTDQDEEH CRKVNEYLNN PPMPGALGAS GSSGHELSAL GGEGGLQSLL GNMSHSQLMQ LIGPAGLGGL GGLGALTGPG LASLLGSSGP PGSSSSSSSR SQSAAVTPSS TTSSTRATPA PSAPAAASAT SPSPAPSSGN GASTAASPTQ PIQLSDLQSI LATMNVPAGP AGGQQVDLAS VLTPEIMAPI LANADVQERL LPYLPSGESL PQTADEIQNT LTSPQFQQAL GMFSAALASG QLGPLMCQFG LPAEAVEAAN KGDVEAFAKA MQNNAKPEQK EGDTKDKKDE EEDMSLD
Explore Proteasomal ubiquitin receptor ADRM1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets